Health / Cancer Research

J&J to Acquire Halda Therapeutics for $3.05 Billion

Johnson & Johnson (J&J) is set to acquire Halda Therapeutics for $3.05 billion in cash, marking a significant expansion of J&J's presence in the oncology space, particularly in treatments for solid tumors and prostate cancer.